Positive Recommendation to Continue Phase 3 Clinical Trial of Leuprolide Injectable Emulsion for the Treatment of Central Precocious Puberty

TAIPEI, April 1, 2024 -- Foresee Pharmaceuticals ( " Foresee " ) today announces the positive safety review by the independent Data and Safety Monitoring Board for its Casppian Phase 3 registration study. The DSMB recommended that Foresee...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials